drugset / Trial / NCT06579703

Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease

NCT06579703

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (\<16yo max 15mg, \>16yo max 30mg) x 1 dose.

Timeline

Start
2024-09-30
Primary completion
2027-07-01
Completion
2028-02-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 15 mg/ml Intravenous
Subject Ketorolac Other / unclassified 30 mg/ml Intravenous